Einzeltreffer — DigiBib

Background: Approximately 10%-20% of prostate cancers progress to metastatic and castration-resistant forms (mCRPC). Radioligand (RLT) therapy with [ 177 Lu]Lu-prostate-specific membrane antigen (PSMA) is an emerging treatment for metastasized mCRPC and its efficacy is assessed not only but also by prostate specific antigen (PSA) measurement after 12 weeks or more after treatment. Our aim was to evaluate the role of early PSA measurement after RLT in predicting overall survival (OS) of mCRPC patients.

Methods: A systematic search on PubMed, Web Of Science and Scopus was performed from January to December 2022. PRISMA guidelines for prognostic studies was adopted. Risk of bias was assessed using quality of prognostic studies (QUIPS).

Results: Twelve studies at low-intermediate risk of bias, were included in the meta-analysis (1646 patients, mean age 70 years). About 50% of patients showed a PSA decline after 1-2 of [ 177 Lu]Lu-PSMA, and more than 30% reported a PSA decline ≥50%. The median OS range for patients with any PSA decline was 13-20 months, while for patients with stable or increased PSA, the median OS fell to 6-12 months. The OS rate for a PSA decline after the one-two [ 177 Lu]Lu-PSMA cycles was 0.39 (95% CI: 0.31-0.50), while OS for a PSA decline ≥50% was 0.69 (95% CI: 0.57-0.83).

Conclusions: A PSA decline is observed in almost 50% of mCRPC patients after 1-2 [ 177 Lu]Lu-PSMA cycles, with a significantly longer OS compared to stable or increased PSA levels, respectively. Accordingly, any PSA decline after 1-2 cycles of therapy should be regarded as a favourable prognostic factor for OS.

Titel:	Prognostic role of early prostate specific antigen changes after [ <superscript>177</superscript> Lu]Lu-PSMA radioligand therapy of metastasized prostate cancer: A meta-analysis.
Autor/in / Beteiligte Person:	Giovanella, L ; Garo, ML ; Cuzzocrea, M ; Paone, G ; Herrmann, K
Link:	Full Text Finder (Volltext)
Zeitschrift:	European journal of clinical investigation, Jg. 53 (2023-09-01), Heft 9, S. e14014
Veröffentlichung:	Oxford : Wiley ; <i>Original Publication</i>: Berlin, New York, Springer-Verlag, on behalf of the European Society for Clinical Investigation., 2023
Medientyp:	academicJournal
ISSN:	1365-2362 (electronic)
DOI:	10.1111/eci.14014
Schlagwort:	Male Humans Aged Prognosis Treatment Outcome Prostate pathology Dipeptides therapeutic use Retrospective Studies Prostate-Specific Antigen Prostatic Neoplasms, Castration-Resistant radiotherapy Prostatic Neoplasms, Castration-Resistant chemically induced
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Meta-Analysis; Journal Article Language: English [Eur J Clin Invest] 2023 Sep; Vol. 53 (9), pp. e14014. <i>Date of Electronic Publication: </i>2023 May 17. MeSH Terms: Prostate-Specific Antigen* ; Prostatic Neoplasms, Castration-Resistant* / radiotherapy ; Prostatic Neoplasms, Castration-Resistant* / chemically induced ; Male ; Humans ; Aged ; Prognosis ; Treatment Outcome ; Prostate / pathology ; Dipeptides / therapeutic use ; Retrospective Studies References: Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019;10:63-89. ; Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144:1941-1953. ; Luengo-Fernandez R, Leal J, Gray A, Sullivan R. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol. 2013;14:1165-1174. ; Zaorsky NG, Lin J, Ba D, et al. The cost of prostate cancer care to society and to patients in the United States. J Clin Oncol. 2019;37:116. ; Howard DH, Quek RGW, Fox KM, Arondekar B, Filson CP. The value of new drugs for advanced prostate cancer. Cancer. 2021;15(127):3457-3465. ; Akaza H, Procopio G, Pripatnanont C, et al. Metastatic castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy: treatment patterns from the PROXIMA prospective registry. Journal of global. Oncology. 2018; 4:1-12. ; Lorente D, Ravi P, Mehra N, et al. Interrogating metastatic prostate cancer treatment switch decisions: a multi-institutional survey. Eur Urol Focus. 2018;4:235-244. ; Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65:1180-1192. ; Verry C, Vincendeau S, Massetti M, et al. Pattern of clinical progression until metastatic castration-resistant prostate cancer: an epidemiological study from the European prostate cancer registry. Target Oncol. 2022;17:441-451. ; Chowdhury S, Bjartell A, Lumen N, et al. Real-world outcomes in first-line treatment of metastatic castration-resistant prostate cancer: the prostate cancer registry. Target Oncol. 2020;15:301-315. ; Barinka C, Rojas C, Slusher B, Pomper M. Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer. Curr Med Chem. 2012;19:856-870. ; Laudicella R, Rüschoff JH, Ferraro DA, et al. Infiltrative growth pattern of prostate cancer is associated with lower uptake on PSMA PET and reduced diffusion restriction on mpMRI. Eur J Nucl Med Mol Imaging. 2022;49:3917-3928. ; Rüschoff JH, Ferraro DA, Muehlematter UJ, et al. What's behind (68)Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns. Eur J Nucl Med Mol Imaging. 2021;48:4042-4053. ; Widjaja L, Werner RA, Ross TL, Bengel FM, Derlin T. PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under (177)Lu-PSMA-617 Radioligand Therapy. Cancers (Basel). 2021;13:2938. ; Fanti S, Goffin K, Hadaschik BA, et al. Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer. Eur J Nucl Med Mol Imaging. 2021;48:469-476. ; Fendler WP, Eiber M, Beheshti M, et al. (68)Ga-PSMA PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017;44:1014-1024. ; Yaxley JW, Raveenthiran S, Nouhaud FX, et al. Risk of metastatic disease on (68) gallium-prostate-specific membrane antigen positron emission tomography/computed tomography scan for primary staging of 1253 men at the diagnosis of prostate cancer. BJU Int. 2019;124:401-407. ; Giraudet AL, Kryza D, Hofman M, et al. PSMA targeting in metastatic castration-resistant prostate cancer: where are we and where are we going? Ther Adv Med Oncol. 2021;13:17588359211053898. ; Sandhu S, Guo C, Hofman MS. Radionuclide therapy in prostate cancer: from standalone to combination PSMA theranostics. J Nucl Med. 2021;62:1660-1668. ; European Medicines Agency. Pluvicto. https://www.ema.europa.eu/en/medicines/human/EPAR/pluvicto. ; Hennrich U, Eder M. [(177)Lu]Lu-PSMA-617 (Pluvicto™): the first FDA-approved Radiotherapeutical for treatment of prostate cancer. Pharmaceuticals (Basel). 2022;15:1292. ; Rahbar K, Bodei L, Morris MJ. Is the Vision of Radioligand therapy for prostate cancer becoming a Reality? An overview of the phase III VISION trial and its importance for the future of Theranostics. J Nucl Med. 2019;60:1504-1506. ; Hofman MS, Emmett L, Sandhu S, et al. The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel-overall survival after median follow-up of 3 years (ANZUP 1603). J Clin Oncol. 2022;40:5000. ; Ahmadzadehfar H, Eppard E, Kurpig S, et al. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget. 2016;7:12477-12488. ; Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091-1103. ; Morris MJ, Bono JSD, Chi KN, et al. Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION). J Clin Oncol. 2021;39:LBA4. ; Ruigrok EAM, van Vliet N, Dalm SU, et al. Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy. Eur J Nucl Med Mol Imaging. 2021;48:1339-1350. ; Gafita A, Heck MM, Rauscher I, et al. Early prostate-specific antigen changes and clinical outcome after (177)Lu-PSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer. J Nucl Med. 2020;61:1476-1483. ; Calopedos RJS, Chalasani V, Asher R, Emmett L, Woo HH. Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2017;20:352-360. ; Kim YJ, Kim YI. Therapeutic responses and survival effects of 177Lu-PSMA-617 Radioligand therapy in metastatic castrate-resistant prostate cancer: a meta-analysis. Clin Nucl Med. 2018;43:728-734. ; Yadav MP, Ballal S, Sahoo RK, Dwivedi SN, Bal C. Radioligand therapy with (177)Lu-PSMA for metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. AJR Am J Roentgenol. 2019;213:275-285. ; Bülbül O, Unek IT, Kefi A, Tuna EB, Bekis R. Factors affecting overall survival and progression-free survival in patients with metastatic castration resistant prostate cancer received (177)Lu PSMA I&T therapy. Hell J Nucl Med Sep-Dec. 2020;23:229-239. ; Scher HI, Morris MJ, Stadler WM, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol. 2016;34:1402-1418. ; Ahmadzadehfar H, Wegen S, Yordanova A, et al. Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [(177)Lu]Lu-PSMA-617. Eur J Nucl Med Mol Imaging. 2017;44:1448-1454. ; Hartrampf PE, Bundschuh RA, Weinzierl FX, et al. mCRPC patients with PSA fluctuations under radioligand therapy have comparable survival benefits relative to patients with sustained PSA decrease. Eur J Nucl Med Mol Imaging. 2022;49:4727-4735. ; Kind F, Fassbender TF, Andrieux G, Boerries M, Meyer PT, Ruf J. Early PSA change after [(177)Lu]PSMA-617 Radioligand therapy as a predicator of biochemical response and overall survival. Cancers (Basel). 2021;14:14. ; Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Rev Esp Cardiol. 2021;74:790-799. Declaracion PRISMA 2020: una guia actualizada para la publicacion de revisiones sistematicas. ; Riley RD, Moons KGM, Snell KIE, et al. A guide to systematic review and meta-analysis of prognostic factor studies. BMJ. 2019;364:k4597. ; Hayden JA, van der Windt DA, Cartwright JL, Cote P, Bombardier C. Assessing bias in studies of prognostic factors. Ann Intern Med. 2013;158:280-286. ; Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12(9). doi:10.1186/1471-2288-12-9. ; Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Response to: practical methods for incorporating summary time-to-event data into meta.Authors’ Reply. ’Trials. 2013;14:391. ; Ahmadzadehfar H, Rahbar K, Baum RP, et al. Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [(177)Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial). Eur J Nucl Med Mol Imaging. 2021;48:113-122. ; Ahmadzadehfar H, Schlolaut S, Fimmers R, et al. Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [(177)Lu]Lu-PSMA-617 radioligand therapy. Oncotarget. 2017;28(8):103108-103116. ; Brauer A, Grubert LS, Roll W, et al. (177)Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2017;44:1663-1670. ; Has Simsek D, Kuyumcu S, Karadogan S, et al. Outcome of 177 Lu-PSMA radionuclide treatment in advanced prostate cancer and its association with clinical parameters: a single-center experience. Clin Nucl Med. 2022;1(47):e521-e528. ; Kessel K, Seifert R, Schafers M, et al. Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving (177)Lu-PSMA-617. Theranostics. 2019;9:4841-4848. ; Khreish F, Ghazal Z, Marlowe RJ, et al. 177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: initial 254-patient results from a prospective registry (REALITY study). Eur J Nucl Med Mol Imaging. 2022;49:1075-1085. ; Rahbar K, Boegemann M, Yordanova A, et al. PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival. Eur J Nucl Med Mol Imaging. 2018;45:12-19. ; Yordanova A, Linden P, Hauser S, et al. The value of tumor markers in men with metastatic prostate cancer undergoing [(177) Lu]Lu-PSMA therapy. Prostate. 2020;80:17-27. ; Rahbar K, Ahmadzadehfar H, Kratochwil C, et al. German multicenter study investigating 177Lu-PSMA-617 Radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017;58:85-90. ; Sadaghiani MS, Sheikhbahaei S, Werner RA, et al. (177) Lu-PSMA radioligand therapy effectiveness in metastatic castration-resistant prostate cancer: an updated systematic review and meta-analysis. Prostate. 2022;82:826-835. ; Rahbar K, Bogeman M, Yordanova A, et al. Delayed response after repeated (177)Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45:243-246. Contributed Indexing: Keywords: [177Lu]Lu-prostate specific membrane antigen; early response; metastatic castration resistant; overall survival; prostate cancer; prostate specific antigen Substance Nomenclature: EC 3.4.21.77 (Prostate-Specific Antigen) ; 0 (Dipeptides) Entry Date(s): Date Created: 20230517 Date Completed: 20230821 Latest Revision: 20230821 Update Code: 20240514

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Prognostic role of early prostate specific antigen changes after [ <superscript>177</superscript> Lu]Lu-PSMA radioligand therapy of metastasized prostate cancer: A meta-analysis.